Signature Cytokines and Immune-Mediated Inflammatory Diseases The ability to block
specific cytokine pathways has revealed pathophysiological differences among autoimmune …

Interleukin-6 (IL-6) is a pleiotropic cytokine with roles in immunity, tissue regeneration, and
metabolism. Rapid production of IL-6 contributes to host defense during infection and tissue …

Despite nearly three decades of advances in the management of rheumatoid arthritis (RA), a
substantial minority of patients are exposed to multiple DMARDs without necessarily …

Recent insights in rheumatoid arthritis (RA) necessitated updating the European League
Against Rheumatism (EULAR) RA management recommendations. A large international …

New treatment strategies have substantially changed the course of rheumatoid arthritis.
Many patients can achieve remission if the disease is recognised early and is treated …

Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor
antagonist, are approved (±methotrexate) in numerous countries throughout the world, for …

Interleukein-6 (IL-6), is produced locally from infectious or injured lesions and is delivered to
the whole body via the blood stream, promptly activating the host defense system to perform …

The COVID-19 pandemic has spread rapidly worldwide. It is common to encounter patients
with COVID-19 with abnormal liver function, either in the form of hepatitis, cholestasis, or …

Abstract Purpose of Review Chimeric antigen receptor (CAR) T cell therapy is an
immunotherapy that has resulted in tremendous progress in the treatment of patients with B …

Tocilizumab (TCZ) is an interleukin-6 (IL-6) inhibitor used for the treatment of rheumatoid
arthritis (RA). It was developed in 2008, and its effectiveness is supported by evidence from …